磷霉素
医学
菌血症
肺炎
内科学
肺炎克雷伯菌
不利影响
抗生素
泌尿系统
碳青霉烯
微生物学
生物化学
生物
基因
化学
大肠杆菌
作者
Pınar Aysert Yıldız,Özge Özgen-Top,Hamid Habibi,Murat Dizbay
标识
DOI:10.1080/1120009x.2022.2149186
摘要
The aim of the study was to evaluate clinical and microbiological efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant K. pneumoniae infections. All adult inpatients receiving 48 h of intravenous fosfomycin, alone or combined with other antibiotics were included in the study. Overall favorable clinical response rate was 75.3% among 94 patients. Clinical response rates were 92.3%, 72.2% and 56.0% for urinary tract infections, bacteremia and pneumonia, respectively. Microbiological eradication was achieved in 55 of 86 patients. 30-day mortality was 33.0%. Adverse events were generally mild. Common adverse events were hypokalemia (37.2%) and hypernatremia (22.3%). Intravenous fosfomycin is an effective antibiotic option with a good safety profile for the treatment of carbapenem-resistant K. pneumoniae infections. The most favorable clinical and microbiological responses are obtained in urinary tract infections. The efficacy of the drug in more severe infections, such as pneumonia and bacteremia, is comparable to the literature.
科研通智能强力驱动
Strongly Powered by AbleSci AI